The QualityStocks Daily Thursday, June 21st, 2018

Today's Top 3 Investment Newsletters

Wolf of Penny Stocks (VPRB) +78.08%

MarketClub Analysis (XBIO) +50.63%

StockMarketWatch (ASCMA) +33.57%

The QualityStocks Daily Stock List

Focus Universal, Inc. (FCUV)

Awesome Penny Stocks, Amigo Bulls, Zacks, Penny Stock Hub, OTC Markets, TradingView, Business Insider, Barchart, Simply Wall St, Stockhouse, Last10K, Stockopedia, CapitalCube, The Street, WhaleWisdom, InvestorsHangout, Financial Content, Street Insider, and Investing News Alerts reported on Focus Universal, Inc. (FCUV), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Focus Universal, Inc. is a universal smart instrumentation platform developer and universal smart device manufacturer in the IOT (Internet of Things) market. The Focus Universal technology features a Universal Smart Instrumentation Platform (USIP). The USIP provides an innovative and universal solution for embedded design, industrial control and monitoring. Focus Universal lists on the OTC Markets’ OTCQB and the Company is based in Walnut, California.

The USIP uses a mobile device or computer to communicate with smart devices to monitor and control any functions. Therefore, it replaces traditional instrument hardware. The features of the Focus Universal USIP include Universal Customization; Cost Saving; Interoperability; Security; Ease of Use; Scalability; Cloud Instrumentation; and Fast Prototyping.

The smart app interface supports real-time data monitoring. It facilitates instrument control and operation. A wireless data logger (Ubiquitor) acts as a link between the smart device and sensor data acquisition module. The Universal Smart Controller (USC) permits a user to control any device by plugging the sensors into the platform using their smartphone.

Regarding the Company’s services, Focus Universal offers Large Scale Custom Installation. It can map out any commercial installation needs and customize a package of devices and sensors to fit any requirements.

This past March, Focus Universal announced that the United States Patent and Trademark Office (USPTO) issued an Issue Notification for U.S. Patent No. 9924295 entitled "Universal Smart Device," which covers a patent application pertaining to the Company's Universal Smart Device. The USPTO had earlier issued a Notice of Allowance for the same patent. Barring any unexpected circumstances, the patent will be valid until 2036.

This week, Focus Universal announced that it entered into a definitive securities purchase agreement with certain eligible purchasers for the purchase of a total of 4,600,000 shares of its common stock (Shares) for a total purchase price of $8.0 million, or $1.75 per share. Focus Universal’s intention is to use the net proceeds of this offering for strategic acquisitions and business development.

Focus Universal, Inc. (FCUV), closed Thursday's trading session at $4.00, up 25.00%, on 606 volume with 5 trades. The average volume for the last 60 days is 115 and the stock's 52-week low/high is $0.25/$4.00.


RepliCel Life Sciences, Inc. (REPCF)

OTCPicks, Global Equity Report, The Green Baron, Club Penny Stocks Network, Streetwise Reports, InvestorSoup, Penny Stock Explosion, Greenbackers, Investor Spec Sheet, StockGuru, TheStockAdvisor, 24-7 Stock Alert, Beacon Equity Research, SmallCapReview, Stock Preacher, Penny Stocks Finder, ShazamStocks, and StockHideout reported on RepliCel Life Sciences, Inc. (REPCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RepliCel Life Sciences, Inc. is a regenerative medicine company. It focuses on the development of cell therapies for aesthetic and orthopedic conditions. These include aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. All of the Company’s product candidates are founded upon RepliCel’s innovative technology using cell populations isolated from a patient's healthy hair follicles. RepliCel Life Sciences has its corporate headquarters in Vancouver, British Columbia.

RepliCel is investing in research that its states has the potential to lead to a number of future products. These include other chronic tendinopathies (patellar tendinosis, tennis elbow, golfer’s elbow, rotator cuff); other dermatologic indications (acne scaring, etc.); gingivitis, and allogeneic versions of RepliCel’s proven autologous cell therapies.

The Company’s product pipeline comprises RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. At present, RCH-01 is being co-developed with, and under exclusive license by, Shiseido for certain Asian countries. Furthermore, RepliCel Life Sciences has developed a proprietary injection device RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications.

In January of this year, RepliCel Life Sciences announced that it signed a Binding Term Sheet with YOFOTO (China) Health Industry Co. Ltd. (YOFOTO) to establish a strategic partnership in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal involves an up-front investment of USD $6,500,000 and potential pre-commercial, non-dilutive milestones payments of another USD $2,800,000.

In addition, the Term Sheet commits YOFOTO to another USD $1,000,000 in potential post-commercial non-dilutive milestone payments, several million in dedicated program funding in Greater China over the next five years, and future royalty payments calculated on gross product sales in the Territory.

In May, RepliCel Life Sciences announced that it now has a new Binding Term Sheet with YOFOTO (China) Health Industry Co. Ltd. that both parties believe represents a stronger deal for both sides and positions them to finalize the transaction in the very short-term. The deal structure in the revised and original binding term sheets remains the same. This is an exclusive license to three RepliCel products for the Territory in exchange for payment through investment, milestones, and program funding and sales royalties.

RepliCel Life Sciences, Inc. (REPCF), closed Thursday's trading session at $0.2571, up 1.22%, on 6,200 volume with 3 trades. The average volume for the last 60 days is 13,760 and the stock's 52-week low/high is $0.2474/$0.546.6


Dthera Sciences (DTHR)

Investors Hub, Barchart, Stockopedia, OTC Markets, MarketWatch, 4-Traders, TradingView, and Simply Wall St reported on Dthera Sciences (DTHR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dthera Sciences is a digital therapeutics company listed on the OTC Markets Group’s OTCQB. The Company works to improve Quality of Life (QoL) and lessen anxiety in residents with Alzheimer’s, Dementia, and isolation. Its emphasis is on developing unique digital QoL therapies for neurodegenerative diseases and oncology. Dthera Sciences has its corporate office in San Diego, California.

Digital Therapeutics is a new subsection of digital health. It directly delivers a therapy software technology. Digital Therapeutics mirror existing, effective treatments. However, it uses technology to scale to a large patient population, amplifying doctors’ and nurses’ ability and efficiency, and decreasing cost of care.

Dthera’s lead product is ReminX (concerning Reminiscence Therapy for Anxiety Reduction). This is an artificial-intelligence-powered digital therapeutic. The design of ReminX is to lessen anxiety and improve QoL in patients with Alzheimer's disease and Dementia.

This product  has completed a successful clinical trial with the University of California San Diego showing its effectiveness as a scalable form of Reminiscence Therapy. Reminiscence Therapy (RT) is discussing or reviewing recognizable memories. This is through looking at photos, and hearing or discussing the familiar stories related to them.  

ReminX is a digital therapeutic that takes personalized stories and delivers a treatment called Reminiscence Therapy to ease stress. Family members utilize the ReminX app to upload photos and provide narration. Seniors pick up their ReminX tablet to watch stories from their own and their loved one’s lives. ReminX is available on IOS and Android.

The patient’s custom tablet plays stories on demand. There is no interface for the patient to learn. Picking up the tablet starts stories. Putting the tablet down stops them. ReminX utilizes a digital assistant to assist in curating content for an individual’s loved one.

In October 2017, Dthera Sciences announced the positive initial results of a pilot Program with CurePSP, a foremost nonprofit centered on neurodegenerative diseases. CurePSP and Dthera earlier engaged in a pilot program in which individuals diagnosed with PSP used ReminX.

The initial results for PSP were definitely positive. As a result, CurePSP and Dthera have agreed to work together to make the ReminX product available for the wider CurePSP community. The hope is to gather more information and make a positive impact in the QoL in as many PSP patients and their families as possible.

Dthera Sciences (DTHR), closed Thursday's trading session at $0.5547, up 33.57%, on 1,358 volume with 2 trades. The average volume for the last 60 days is 4,213 and the stock's 52-week low/high is $0.4153/$30.00.


Aerpio Pharmaceuticals, Inc. (ARPO)

HighRisingStocks, Street Insider, OTC Markets, HotStockCafe, OTC Stock Picks, and MarketWatch reported earlier on Aerpio Pharmaceuticals, Inc. (ARPO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Aerpio Pharmaceuticals, Inc. concentrates on first-in-class treatments for ocular diseases. The Company’s lead compound is AKB‐9778. This is a small molecule activator of the Tie2 pathway. It is in clinical development for the treatment of non-proliferative diabetic retinopathy. A biopharmaceutical Company, Aerpio Pharmaceuticals is based in Cincinnati, Ohio.

Presently, AKB-9778 is in a Phase 2b study  (TIME-2b)  for the treatment of non-proliferative diabetic retinopathy (NPDR). This is a disease that affects millions of people around the world. Diabetic Retinopathy (DR) is a complication of diabetes caused by damage to blood vessels in the retina. AKB-9778 is undergoing development as a subcutaneous injection.

Furthermore, Aerpio Pharmaceuticals’ second program in development builds on its inventive approach to targeting the Tie2 pathway. ARP-1536 is a humanized monoclonal antibody. It works by binding the extracellular domain of VE-PTP,  inhibiting its ability to interact with the Tie2 receptor. This prevents the inactivation of Tie2. In addition, it promotes vascular stability.

ARP-1536 is in pre-clinical development. The Company’s plan is to develop ARP-1536 in combination with anti-VEGF therapy for the treatment of wet age-related macular degeneration (AMD)  and diabetic macular edema (DME).

Moreover, Aerpio Pharmaceuticals’ AKB-4924 is in Phase 1 clinical development. The Company’s plan is to develop it as a once-daily, oral treatment for inflammatory bowel disease (IBD). AKB-4924 is a unique small molecule inhibitor of prolyl-hydroxylase domain enzymes (PHDs).

Last week,  Aerpio Pharmaceuticals announced the completion of patient enrollment in its TIME-2b study. This is a Phase 2b clinical trial designed to measure the efficacy and safety of Aerpio’s lead candidate AKB-9778 for patients with moderate to severe non-proliferative diabetic retinopathy.

The TIME-2b study is a double-masked, placebo-controlled, multi-center trial. It has enrolled 167 patients randomized to receive 48-weeks of treatment with either AKB-9778 15 mg subcutaneously once daily, AKB-9778 15 mg subcutaneously twice daily, or placebo subcutaneously twice daily.

The main endpoint of the TIME-2b study is the percentage of patients who improve by two or more steps in diabetic retinopathy severity score (DRSS) in the study eye.

Aerpio Pharmaceuticals, Inc. (ARPO), closed Thursday's trading session at $4.07, up 1.75%, on 3,700 volume with 6 trades. The average volume for the last 60 days is 7,912 and the stock's 52-week low/high is $3.29/$6.75.


Innovative Food Holdings, Inc. (IVFH)

The Bowser Report,, Stock Guru, and FeedBlitz reported earlier on Innovative Food Holdings, Inc. (IVFH), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Innovative Food Holdings, Inc. is an industry leading specialty food platform. The Company, through its subsidiaries, is a foremost nationwide provider of direct from source specialty foods, healthcare foods, gluten free foods, and artisanal foods, to the professional foodservice market. Perishable product is delivered direct to the Company’s kitchen the next day via overnight delivery. Non-perishable product is delivered direct to customers. Innovative Food Holdings is headquartered in Bonita Springs, Florida.

For Chefs (Chef Direct), the Company’s vertically-integrated platform enables it to source 7,000-plus specialty foods from around the world and deliver within 24-72 hours. Innovative Food Holdings’ subsidiaries include Artisan Specialty Foods and Innovative Gourmet.

Artisan Specialty Foods is a nationwide specialty food distributer, re-packer, and importer. Artisan serves hundreds of customers in the Chicago area. Additionally, it serves as a nationwide fulfillment center for other Innovative Food Holdings subsidiaries operating in the foodservice and direct-to-consumer markets.

In the direct-to-chef foodservice market, available products include origin specific seafood, exotic meats and game, dry-aged meats, exotic fruits and vegetables, specialty chocolates, artisanal cheeses, and imported specialties. In addition, available products include caviar, wild and cultivated mushrooms, micro-greens, heirloom and baby produce, organic farmed and manufactured food products, estate-bottled olive oils, aged vinegars,  and healthcare food products.

  Innovative Food Holdings supplies chefs with unique, organic, sustainable, and artisanal products sourced from all areas internationally. The Company markets its  products directly to the consumer, by way of its website at

The Company serves restaurants, hotels, country clubs, national chain accounts, casinos, and catering houses. Many of its products are used each day by a host of some of the top  professional chefs throughout  the United States.

At the end of January 2018, Innovative Food Holdings announced that its subsidiary, Innovative Gourmet, acquired substantially all the assets of one of North America’s top online gourmet food and gift retailers. The business will operate under igourmet’s valued and trusted trade name.

Mr. Sam Klepfish, Innovative Food Holdings’ Chief Executive Officer, said, “The acquisition of igourmet’s business is synergistic to our current mission of providing small specialty food companies direct access to the kitchens of end users nationwide. Our professional management systems will benefit igourmet and they will serve as an additional distribution center for us.”

igourmet offers a broad variety of high quality gourmet and specialty food products by way of, and via a full line of omnichannel partners. Furthermore, igourmet offers an extensive array of specialty food products to restaurants, specialty retailers and other business establishments through its specialty foodservice division.

Innovative Food Holdings, Inc. (IVFH), closed Thursday's trading session at $0.770025, up 1.83%, on 5,180 volume with 6 trades. The average volume for the last 60 days is 90,791 and the stock's 52-week low/high is $0.573/$1.38.


Centerra Gold, Inc. (CAGDF)

Discovery Stocks, MarketWatch, OTC Markets, Barchart, Investors Hangout, Insider Financial, Resource World, 24hgold, Stockhouse, TipRanks, Wallet Investor, 4-Traders, Morningstar, Barron’s, InvestorsHub, GuruFocus, YCharts, InvestorPoint, CapitalCube, Stockscores,, The OTC Reporter, The Street, Canadian Mining Journal, The Northern Miner, Marketbeat, The Stock Market Watch, and Trading View reported on Centerra Gold, Inc. (CAGDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Centerra Gold, Inc. is a gold mining and exploration company headquartered in Toronto, Ontario. The Company engages in the operation, exploration, development and acquisition of gold properties in North America, Asia and other markets around the world. Centerra has two flagship assets. One is the Mount Milligan Mine in British Columbia. The other is the Kumtor Mine in the Kyrgyz Republic. Centerra Gold’s wholly-owned subsidiary is AuRico Metals, Inc.

Centerra Gold is the largest Western-based gold producer in Central Asia. The Company’s aim is to build shareholder value through maximizing the potential of its current properties and taking advantage of its financial strength and experience to acquire new long-life, low-cost projects. Centerra is also building its next gold mine, the 100 percent owned Öksüt Gold Mine in Turkey.

In 2017, Centerra Gold produced 785,316 ounces of gold and 53.6 million pounds of copper. The Kumtor Mine in the Kyrgyz Republic has produced greater than 11.5 million ounces of gold between 1997 and the end of 2017.

The Mount Milligan Mine in British Columbia is a long life, low-cost gold/copper mine. The Company’s assets also include the former Boroo Mine in Mongolia that produced more than 1.8 million ounces of gold from 2004 to 2016. It is now in care and maintenance waiting for the development of the Gatsuurt Project.

Centerra Gold’s assets also include the late stage Kemess development project in British Columbia, and the Greenstone development project in the Province of Ontario. Moreover, assets also include the Endako and Thompson Creek primary molybdenum mines in British Columbia and Idaho, respectively, which are now on care and maintenance. In addition, assets include the Langeloth Metallurgical Facility in Pennsylvania.

In May, Centerra Gold announced that its wholly-owned subsidiary, AuRico Metals entered into agreements with Triple Flag Mining Finance Bermuda Ltd. in connection with the sale of AuRico Metals’ royalty portfolio and a silver stream on the Kemess project for combined total proceeds of US$200 million.

The Royalty Sale comprises the sale of AuRico Metals’ royalty portfolio, together with new 0.5 percent, 2.0 percent and 2.0 percent Net Smelter Returns (NSR) royalties on AuRico’s Kliyul, Chuchi and Redton exploration properties, respectively, for up-front cash proceeds of US$155 million. This is subject to customary adjustments, including an economic effective date of April 1, 2018.

Yesterday, Centerra Gold announced that it agreed with the Government of the Kyrgyz Republic to further extend the First Longstop Date under the Strategic Agreement for Environmental Protection and Investment Promotion earlier entered into with the Government of the Kyrgyz Republic on September 11, 2017. The First Longstop Date is the date by which all conditions precedent to the completion of the Strategic Agreement are required to be satisfied. It has been further extended by agreement of all the parties from June 22, 2018 to July 23, 2018.

Centerra Gold, Inc. (CAGDF), closed Thursday's trading session at $5.28, down 0.38%, on 10,340 volume with 22 trades. The average volume for the last 60 days is 38,649 and the stock's 52-week low/high is $4.71/$7.62.


Protalex, Inc. (PRTX)

Zacks, TopStockAnalysts, StreetInsider, and OTCPicks reported on Protalex, Inc. (PRTX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Protalex,  Inc.  is a clinical-stage Biopharmaceutical Company listed on the OTCQB. The Company’s focus is on the development of a class of drugs for treating autoimmune and inflammatory diseases. These include RA  (Rheumatoid Arthritis) and ITP  (Immune Thrombocytopenia). Protalex’s lead product is PRTX-100. This is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria.  Protalex is headquartered in Florham Park, New Jersey.

Rheumatoid arthritis (RA) is an autoimmune disease. Immune Thrombocytopenia (ITP) is a blood disorder. Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP through decreasing the immune-mediated destruction of the platelets. Protalex has open IND’s for the treatment of RA and ITP in the U.S., and in Europe, an open IMPD for ITP.

PRTX-100 can  (at very low concentrations) bind to human B-lymphocytes and macrophages and to modulate immune processes. PRTX-100 is administered as a short intravenous infusion.  

PRTX-100 has been granted Orphan Drug Designation in the U.S. and in Europe for the treatment of ITP. This status provides commercial exclusivity benefits, tax credits for certain research, potential research grants and a waiver of the New Drug Application user fee in the U.S. At present, it is the subject of clinical studies in the U.S. and Europe.

This past April, Protalex announced that it enrolled the first of three patients in cohort four of its U.S./U.K. Phase 1/2 trial evaluating PRTX-100 for the treatment of adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-202 Study). The fourth cohort was initiated after a planned, interim analysis of safety and efficacy data from cohort three. Patient one, based in the United States, received 12.0 micrograms/kg. This is double the dose used in the previous cohort of 6.0 micrograms/kg.

Last week, Protalex announced preliminary findings that its lead drug candidate PRTX-100 lessened disease activity in a second, confirmatory mouse study of myasthenia gravis (MG). The study was conducted by the Laboratory for Myasthenia Gravis Research at George Washington University. MG is an autoimmune disorder mediated by anti-self antibodies, which react with the neuromuscular junction. The study demonstrated potential clinical benefits of PRTX-100 in mice with established MG symptoms.

Furthermore, last week, Protalex announced that data highlighting results from its European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP) (the PRTX-100-203 Study) were presented in a poster on June 15, 2018 at the European Hematology Association 23rd Annual Meeting in Stockholm.

The poster highlights findings from 15 patients enrolled in all five dose escalating cohorts and included seven women and eight men ages 22 to 82. The main goal of the study was to evaluate the safety of five different doses of PRTX-100. The data demonstrated that PRTX-100 had an acceptable safety profile across the dose range studied.

The poster is entitled “A Phase 1B Open-Label Dose-Escalation Study of PRTX-100, a Highly Purified Form of Staphylococcal Protein A (SpA), in Adult Patients with Persistent/Chronic Immune Thrombocytopenia.”

Protalex, Inc. (PRTX), closed Thursday's trading session at $0.50, even for the day. The average volume for the last 60 days is 2,485 and the stock's 52-week low/high is $0.312/$3.00.


Innovus Pharmaceuticals, Inc. (INNV)

1-2-3 Stock Alerts, BUYINS.NET,  Promotion Stock Secrets, TopPennyStockMovers, DSR News, Penny Stock Hub, PHUB News, Wall Street Mover, HotTopPennyStocks,, PennyPickAlerts, Fortune Stock Alerts,  Penny Stock Bets, StockMister, SeeThruEquityResearch,  Penny Stock Circle,  and OTPicks reported earlier on Innovus Pharmaceuticals, Inc. (INNV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Innovus Pharmaceuticals, Inc. is a developing Over-The-Counter (OTC) consumer goods and specialty pharmaceutical company. It involves in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharmaceuticals is based in San Diego, California.

The Company generates revenues from its lead products BTH® Testosterone Booster; BTH® Human Growth Agent; Zestra® for female arousal and EjectDelay® for premature ejaculation. Innovus Pharmaceuticals has plans to enter the oncology supportive care OTC market with an exclusive license to two GRAS (Generally Recognized As Safe by the U.S. FDA)-listed compounds, thymol and carvacrol, for cachexia and muscle growth and repair, from the University of Iowa Research Foundation.  

Innovus has an additional five marketed products. These include Sensum+® for the indication of decreased penile sensitivity; Zestra Glide®; Vesele® for promoting sexual health;  RecalMax™ for promoting brain and cognitive health; Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality;  BTH Vision Formula;  BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if the Company’s Abbreviated New Drug Application (ANDA)  receives approval by the Food and Drug Administration  (FDA).

Innovus Pharmaceuticals has started a pre-clinical and clinical program intended to evaluate the safety and efficacy of the combination of its supplement Vesele® for promoting sexual health with sildenafil indicated for treating erectile dysfunction. Sildenafil in the United States sells under the name Viagra® by Pfizer, Inc.

Vesele® is a proprietary oral formulation of L-Arginine and L-Citrulline with the natural absorption enhancer Bioperine®. Vesele® was formulated to increase blood flow and nitric oxide production.

Innovus launched AllerVarx™ in the U.S.  in 2017.  AllerVarx™ is a clinically proven supplement, scientifically formulated for the relief of allergy symptoms. AllerVarx™, selling in Europe under the brand name Lertal®, is a product the Company exclusively in-licensed for the U.S. and Canada from NTC s.r.l. - an Italian company.

Recently, Innovus Pharmaceuticals announced the approval of its Natural Health Product (NHP) License in Canada for its Apeaz™ product. Apeaz™ is a drug in the U.S. for arthritis pain relief.

Apeaz™ will either be sold by itself as an NHP in Canada or in the future, potentially sold with Innovus Pharmaceuticals’ supplement, ArthriVarx™, a nutritional supplement designed to promote and maximize joint health, when that product is presented to Health Canada for approval.

This month, Innovus Pharmaceuticals announced that the human clinical trial for the patented formulation in its UriVarx® product for bladder health was published in the peer reviewed journal, BMC Complementary and Alternative Medicine (Schoendorfer et al. BMC Complementary and Alternative Medicine (2018) 18:42).

The team of Dr. Niikee Schoendorfer in Australia in collaboration with Innovus Pharmaceuticals’ UriVarx® licensing partner Seipel Group, Ltd conducted the study. The outcome of the study demonstrated statistical significance and clinical relevance in lessening symptoms of Overactive Bladder (OAB), urinary frequency and/or urgency and incontinence.

Innovus Pharmaceuticals, Inc. (INNV), closed Thursday's trading session at $0.109, up 5.83%, on 750,067 volume with 87 trades. The average volume for the last 60 days is 488,005 and the stock's 52-week low/high is $0.078/$0.21.


North America Frac Sand, Inc. (NAFS)

BestDamnPennyStocks,  PennyPickAlerts, TheNextBigTrade,  Stock Commander, PennyStockProfessor, SMS Penny Picks, DSR News,  eliteotc, Wall Street Beauties, WINNINGOTC,  Fortune Stock Alerts, and Penny Stock Hub reported previously on North America Frac Sand, Inc. (NAFS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

North America Frac Sand, Inc. is a development stage company that owns renewable land leases with the right to extract frac sand from significant mineral deposits situated in the Province of Saskatchewan. The Company has 29,900 acres of leases and lease options 30 kilometers east of Saskatoon. North America Frac Sand is based in Ossian, Indiana.

In 2015, North America Frac Sand acquired North America Frac Sand (CA) Ltd. and its acres of leases.  In 2016, North America Frac Sand announced the completion of the due diligence obligatory preceding the decision to close on the acquisition of North America Frac Sand (CA) Ltd. (NAFS-CA).

North America Frac Sand’s strategy is to realize a major presence in the frac sand industry through developing a long term, high quality, and secure supply of frac sand for the oil & gas industry in Western Canada and the Northwestern U.S. Frac Sand is a proppant. It is used in the oil & gas industry as part of the hydraulic fracturing process - a way to enhance flow to the wellhead.

North America Frac Sand’s short-term plan is to prove out the balance of its major resource. Its long-term plan is to commence shipments of frac sand as soon as possible.

Furthermore, the Company’s strategy is to develop and maximize the mineral deposit under its land and optioned leases. Its strategy is also to develop a long-term relationship with well service and oil & gas companies that focus on quality service and product. In addition, North America Frac Sand’s strategy involves providing a year-round supply of frac sand to customers.

North America Frac Sand received its initial "Technical Report" addressing its Eagle Creek Property in Saskatchewan on May 25, 2017. The Technical Report covers exploration so far on a portion of the Company’s leased areas (around 12,100 hectares [29,900 acres]).

At the end of April, North America Frac Sand announced that it entered into a Letter of Intent (LOI) with Urban Select to sell 100 percent of the rights to roughly 29,900 leased acres in the Province of Saskatchewan, more usually known as the Eagle Creek Property.  With this LOI, Urban Select will have an exclusive period of up to 60 days of signing the LOI to conduct its due diligence on Eagle Creek.

Upon satisfactory due diligence, a Definitive Agreement will be executed whereby Urban Select can acquire the Property in consideration of issuing 20 million common shares of Urban Select to North America Frac Sand. Urban Select's intention is to assign its rights to the Property to a newly incorporated Saskatchewan subsidiary.

Mr. Joe Kistler, Chief Executive Officer of North America Frac Sand, said in April, "This is a great opportunity for NAFS to move the Eagle Creek project forward with an experienced investment management team located in Canada.”

North America Frac Sand, Inc. (NAFS), closed Thursday's trading session at $0.008, even for the day. The average volume for the last 60 days is 25,590 and the stock's 52-week low/high is $0.006/$0.0299.


Anfield Energy, Inc. (ANLDF)

Streetwise Reports, InvestorsHub, MarketWatch, OTC Markets, Stockhouse, and Investing News reported on Anfield Energy, Inc. (ANLDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Anfield Energy, Inc. engages in the acquisition, exploration, development, and production of mineral properties in the United States. The Company is a uranium development and near-term production enterprise. Anfield is concentrating on two production centers - the Irigary ISR (in-situ recovery) processing plant in Wyoming and the Shootaring Canyon Mill in Arizona/Utah. Anfield Energy is based in Vancouver, British Columbia.

The Company’s commitment is to becoming a top-tier energy-related fuels supplier through creating value via sustainable, efficient growth in its energy metals assets. Its uranium assets comprise conventional mining claims and State leases in southeastern Utah, Colorado, and Arizona. Anfield’s conventional uranium assets include the Velvet-Wood Project, the Frank M Uranium Project, and the Findlay Tank breccia pipe.

The Company’s key asset is the Shootaring Canyon Mill in Garfield County, Utah. The Shootaring Canyon Mill is strategically located within one of the historically most prolific uranium production areas in the United States. Furthermore, it is one of only three licensed uranium mills in the United States. In 2017, Anfield Energy continued advancing the Shootaring Canyon Uranium Mill license towards operational status with the Utah Division of Waste Management and Radiation Control.

Concerning the Irigaray ISR Processing Plant (Resin Processing Agreement), the Company’s ISR mining projects are in the Black Hills, Powder River Basin, Great Divide Basin, and Laramie Basin, Shirley Basin, and Wind River Basin regions in Wyoming. These consist of 2,667 federal mining claims, 56 Wyoming State leases, and 15 private leases acquired from Uranium One in September 2016.

Anfield Energy’s Clarkson Hill project consists of roughly 500 acres of the mineral holdings of the Company. The Clarkson Hill project includes 25 unpatented mining lode claims situated about 20 air miles southwest of Casper, Wyoming.

Anfield will evaluate the feasibility of adding a vanadium processing facility to its Shootaring Canyon uranium mill. This reflects its intention to capitalize on potential opportunities as vanadium continues to become an even-more relevant commodity in the energy sector.

Anfield Energy announced in December of 2017 a conceptual vanadium exploration target at its Velvet-Wood Mine in Utah. BRS Engineering completed an Exploration Target report, entitled "Velvet-Wood Vanadium Exploration Target, National Instrument 43-101, Utah, U.S.A.", with effective date of December 11, 2017 that provides a vanadium exploration target of between 6.3Mlbs and 9.7Mlbs at a grade of between 0.4 percent V2O5 and 0.61 percent V2O5.

Anfield engaged BRS Engineering to update the Company’s NI 43-101 Preliminary Economic Assessment (PEA) related to the Velvet-Wood Mine to include a vanadium milling circuit as part of a production scenario.

This past April, Anfield Energy announced the acquisition of an extensive exploration database of mining projects centered chiefly on uranium and vanadium properties in the Western U.S. The new database, together with the Company’s already considerable uranium database, constitutes one of the largest depositories of uranium exploration data in the Western U.S.

Also in April, Anfield Energy announced that it identified vanadium exploration targets in its recently-acquired exploration database of mining projects in the Western U.S. The targets are in Colorado and Utah. They are considered complementary to the Company’s Utah-based Shootaring Canyon mill as Anfield Energy could include a vanadium processing circuit on this asset. Additionally, these vanadium projects could serve as a potential extended vanadium project pipeline beyond the Velvet-Wood uranium/vanadium project.

Anfield Energy, Inc. (ANLDF), closed Thursday's trading session at $0.156, down 10.86%, on 62,003 volume with 15 trades. The average volume for the last 60 days is 43,727 and the stock's 52-week low/high is $0.022/$0.4149.


BioHiTech Global, Inc. (BHTG)

Zacks, MarketWatch, and TradingView reported on BioHiTech Global, Inc. (BHTG), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

BioHiTech Global, Inc. is a green technology business headquartered in Chestnut Ridge, New York.  The Company provides  unique data-driven solutions for food waste disposal. It develops and deploys innovative and disruptive waste management technologies. BioHiTech Global is a leader in zero waste solutions for businesses and municipalities of all sizes.  The Company’s shares trade on the OTC Markets Group’s OTCQB.

BioHiTech Global provides waste management solutions to a global customer base covering a complete set of technology-based disposal options that can have a significant  impact on waste generation. This is while providing a true zero landfill environment. 

BioHiTech Global has launched its BioHiTech Alto™. This is a next generation interactive industrial communication technology. It permits users to communicate intelligently with industrial equipment in real-time.  BioHiTech Alto is an important new element of the Company’s complete food waste solution that uses data and analytics to help drive smarter business decisions.

Moreover, the Company collaborated with Natural Systems Utilities to convert commercial food waste to energy. Furthermore, it launched BioHiTech Cirrus. This is a mobile application (app) for consummate insight into the waste stream.

In 2016, BioHiTech Global expanded its waste stream product offering  with the launch of Entsorga North America. The Entsorga North America undertaking expands the Company’s product offering towards providing disruptive, clean technology solutions that progress the international movement towards sustainability and zero waste initiatives.

Entsorga North America will manage Apple Valley Waste Conversions LLC, which is an Entsorga North America part-owned subsidiary, the company that holds an exclusive license to deploy the proprietary Entstorga HEBioT Mechanical Biological Treatment (MBT) technology across the northeastern U.S. The HEBioT MBT system converts food waste, plastics, and other carbon-based materials from the mixed municipal solid waste (MSW) stream into an Environmental Protection Agency (EPA) recognized alternative fuel source. The proprietary HEBioT process recovers close to 80 percent of municipal solid waste.

This past November, BioHiTech Global announced that it completed the acquisition of its first HEBioT renewable waste facility license from Ensorgafin S.P.A (Entsorga) in exchange for a combination of roughly 1,036,000 shares of BioHiTech common stock and $838,000 in cash to be paid through March 31, 2018. The Company controls the exclusive U.S. development rights for Entsorga's patented HEBioT solid waste processing technology in 11 north-eastern States and also the District of Columbia.

Recently, BioHiTech Global announced that a top restaurant and nightlife company with numerous venues in the U.S., has deployed BioHiTech's sustainable food waste disposal solution in seven of its New York City venues. The design of BioHiTech Global's Revolution Series Digesters are to cost effectively meet the needs of the restaurant market segment and many other small volume food waste generators by way of its regulatory compliant digestive technologies.

BioHiTech Global has partnered with Kinderhook Industries. Kinderhook is a private investment firm. It manages greater than $2 billion of committed capital. BioHiTech Global has partnered with Kinderhook to create a "next generation" environmental services platform enterprise.

The two companies, via a series of transactions, completed the acquisition of Gold Medal Services, LLC, a market leader in municipal, commercial, and industrial solid waste collection in the Philadelphia and Southern New Jersey markets as a wholly-owned subsidiary of Gold Medal Group, LLC, a newly created company majority owned by Kinderhook.

BioHiTech Global acquired a 9.2 percent interest in Gold Medal in exchange for 500,000 shares of common stock. In addition, the Company has an option to acquire an additional $5M interest in Gold Medal over the next year.

BioHiTech Global, Inc. (BHTG), closed Thursday's trading session at $4.1092, up 0.47%, on 4,990 volume. The stock's 52-week low/high is $2.68/$9.50.


Cannabis Sativa, Inc. (CBDS)

Flagler Financial Group, Promotion Stock Secrets, Jason Bond,, TopPennyStockMovers, Stockgoodies, Cannabis Financial Network News, Greenbackers, TheMicrocapNews, TopStockAnalysts, Top Pros’ Top Picks, Insider Financial, Darwin Investing Network, Wall Street Mover, Stock Beast, smartOTC, and Real Pennies reported previously on Cannabis Sativa, Inc. (CBDS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cannabis Sativa, Inc. engages in branding and licensing via its 'hi' intellectual properties. The Company engages,  through its subsidiaries, Wild Earth Naturals and "hi" Brands International, Inc., in the research, development, and licensing of specialized natural products. These include formulas, edibles, topicals, recipes, and also delivery systems. Cannabis Sativa has been active in pursuing Intellectual Property  (IP) and has successfully acquired an increasing portfolio of IP.  Cannabis Sativa is headquartered in Mesquite, Nevada.

Cannabis Sativa’s goal is to license the "hi" brand to distributors and producers of quality products and to other ancillary participants in the retail cannabis industry. The Company brands, licenses, innovates, and markets first-class plant-derived topical creams, transdermals, balms, sublinguals, lubricants, and edibles for medical and recreational marijuana consumers, and legal nutraceuticals and branded merchandise for consumers in general.

Cannabis Sativa has its Wild Earth Naturals offerings. The Company offers the Wild Earth Naturals line of CBD Water and cosmetic products designed to use organic and natural ingredients. These include CBD and hemp seed oil.

Cannabis Sativa’s wholly-owned subsidiary, Hi Brands International, entered into an agreement with Centuria Natural Foods, Inc. to market their proprietary CBD Rich Hemp Oil products. Their CBD capsules are marketed under the name, "hi CBD." 

The Company has acquired a majority ownership interest in iBudtender, Inc., a Colorado corporation. Also, it entered into an agreement to acquire a 49 percent ownership interest in a nine-acre property in Los Angeles County, California.

The ownership group’s plan is to lease the property to an industrial hemp farm operator. The operator will conduct farming activities under the Industrial Hemp provisions of California's Adult Use Marijuana Act (Prop 64).

Cannabis Sativa  entered into a license agreement for the manufacture, marketing, and sale of its White Rabbit products in California. The Company closed its acquisition of the White Rabbit brand of cannabis sprays and cannabis mints. This acquisition includes the exclusive and proprietary product formulations, product mixes, manufacturing methods, and branding.

The White Rabbit product line now comprises fast-acting low dose cannabis oral sprays and low dose cannabis mints. Cannabis Sativa has developed a "hi" branded infused honey product (hi honey) made from rich African honey and infused with CBD or THC.

Cannabis Sativa acquired a controlling interest in PrestoCorp (a.k.a. PrestoDoctor). This is an online telemedicine platform. It provides access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology.

This past December, Cannabis Sativa announced that its PrestoDoctor subsidiary is expanding its online medical marijuana recommendation services into New York. At present, PrestoDoctor serves patients through its online platform and with dispensary kiosks operating in California and Nevada. It will now extend its online services to patients located in New York State.

Cannabis Sativa looks for strategic partners for acquisition of operating companies, intellectual property (IP) and other assets that fit within its corporate vision. Furthermore, the Company holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, as well as owns patent pending and trade secret formulas and processes.

Cannabis Sativa, Inc. (CBDS), closed Thursday's trading session at $4.048, down 0.30%, on 64,844 volume with 224 trades. The average volume for the last 60 days is 64,413 and the stock's 52-week low/high is $2.61/$9.74.


Vitality Biopharma, Inc. (VBIO)

SmallCap Network, Stock Beast, and Promotion Stock Secrets reported earlier on Vitality Biopharma, Inc. (VBIO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Vitality Biopharma, Inc.’s dedication is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012,  the Company has developed a unique capability to produce molecules through glycosylation, a form of enzymatic biosynthesis that was originally developed to improve the taste of stevia. The platform is well suited for the discovery of new pharmaceutical products.  Vitality Biopharma has its corporate headquarters in Los Angeles, California.

Late in 2015,  the Company successfully modified cannabidiol (CBD), which is not psychoactive, and in continuing work has created a novel class of pharmaceuticals named cannabosides. Cannabosides, upon ingestion, can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits. This is while reducing or avoiding the systemic delivery of THC into the bloodstream.

Vitality Biopharma completed preclinical pharmacokinetics studies with its proprietary THC glycosides to analyze their bioavailability. It has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain, enabling their formulation within pharmaceuticals where drug psychoactivity will be reduced or eliminated.

The Company can biosynthesize cannabinoid glycosides (cannabosides) by way of enzyme biosynthesis.  Vitality Bippharma is one of only a very few groups around the world who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of stevia (steviol glycosides).

The Company has obtained positive results demonstrating antimicrobial activity of cannabinoids. It filed for patent protection on the use of cannabinoid compounds for the treatment of microbes. This includes Clostridium difficile and other "superbug" pathogens.

Vitality Biopharma announced in October 2017 the achievement of a biosynthesis breakthrough. It has developed a proprietary biosynthesis technology that can modify cannabinoids to create pharmaceutical prodrugs that have no psychoactivity and that can provide targeted disease treatment. The process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds named cannabinoid glycosides, or cannabosides.

Vitality Biopharma has introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. The Company is focusing initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation. Its plan is to complete a first-in-man clinical study in the first half of this year.

The treatment indications Vitality Biopharma plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome (a severe form of opiate-induced abdominal pain).

Mr. Robert Brooke, Chief Executive Officer and Co-Founder of Vitality Biopharma, said, “As independent clinical studies are demonstrating the therapeutic effects of THC, we are well positioned with our VITA-100 gut-restricted prodrug formulation.”

Vitality Biopharma submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA).  With approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease.

Vitality Biopharma, Inc. (VBIO), closed Thursday's trading session at $1.70, up 11.84%, on 334,709 volume with 610 trades. The average volume for the last 60 days is 84,343 and the stock's 52-week low/high is $1.05/$2.37.


The QualityStocks Company Corner

Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF)

The QualityStocks Daily Newsletter would like to spotlight Marifil Mines Ltd. (MFMLF).

Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF), which is engaged in an aggressive campaign for growth within the lithium space in Argentina, announced today that it has engaged the corporate communications expertise of NetworkNewsWire ("NNW").

Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF), headquartered in Vancouver, Canada, is engaged in the exploration, evaluation and acquisition of mineral rich resource properties in Argentina. A rising global demand for cobalt and lithium is generating interest in Marifil Mines and its resources located within South America’s famed “Lithium Triangle,” which include 15,267 hectares spanning its recently acquired Ratones and Fraile claims, as well as two lithium properties covering the southern portions of the Carachi Pampa salar in the Argentine province of Catamarca.

The company’s property also includes the Las Aguilas nickel-copper-cobalt deposit property, with more than four contiguous claims in the San Luis province of Argentina. The Las Aguilas property, which is 100% owned by Marifil, is noted as one of the largest cobalt properties in Argentina. Other noteworthy properties in the company’s portfolio include the Toruel copper-silver property, with more than two contiguous claims, and additional potash properties in Punta Colorada, Pedernal and El Carmen.

Marifil’s sizable portfolio of cobalt and lithium claims in what is recognized as the world’s most prolific mining jurisdiction for these resources strategically positions the company to benefit as global initiatives push demand for lithium-ion batteries toward a frenzy. Zion Market Research, a leading research and consulting firm, has forecast that the lithium-ion battery market could hit $67 billion by 2022, realizing a CAGR of more than 13.7% from 2017-2022. Both lithium and cobalt are major components of these energy storage solutions, with industry data indicating that the battery industry currently consumes roughly 42 percent of global cobalt production.

The company is reviving a lithium exploration program that was active in Argentina a decade ago, building on an unexplored mine it owns there. Marifil will utilize a large proprietary geologic and geochemical data base it developed during its 2009 lithium exploration program in the Salta and Catamarca province sites to resume lithium exploration in the region.

Applications for a second mine and negotiations to purchase a third property are underway, which would establish a significant property portfolio of ‘salar’ brine evaporation lakes. Hydrothermal solutions emanating from regional faults in area volcanoes often enrich the brine with lithium, boron, potassium and magnesium.

In addition to nearly 152,000 acres of lithium-staked properties, Marifil owns 887 acres of land for cobalt exploration and 91,565 acres of gold mining rights in an advanced exploration stage in San Roque that company engineers indicate has high gold discovery potential with “excellent infrastructure and mining friendly politics.”

To date, more than $7.5 million has been invested assessing Marifil’s flagship San Roque gold property, including nearly 16,000 meters of diamond core drilling. The property is jointly owned by Marifil and Novagold Resources, with Marifil holding a 51% stake and serving as the current project operator. The company recently commenced a drilling campaign to further evaluate several deposits of significant gold-silver-indium-lead-zinc mineralization on a 4-kilometer-long zone.

Marifil has closed a private placement funding for $2 million that will inject additional life into the company. Proceeds from the funding will benefit acquisition plans, the ongoing drilling program at Marifil’s gold claim and other output from its general working capital accounts.

Robert Abenante, a chartered professional account, serves as president and chief executive officer of the company. He has extensive experience in the public markets and has served as an officer and director of several public and private companies across various industries, with particular success in the mining sector.

Marifil Mines Ltd. (MFMLF), closed the day's trading session at $0.1542, up 14.05%, on 2,000 volume with 3 trades. The average volume for the last 60 days is 1,725 and the stock's 52-week low/high is $0.01/$0.165.

Recent News


Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (OTC: MCOA) and joint venture partner Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) this morning posted an update on their hemp project in northeast New Brunswick. To view the full press release, visit: Also today, CannabisNewsWire released an editorial featuring Marijuana Company of America. To view the full publication, titled “Dangers Lurking in Synthetic CBD Underscore Value of Quality Product,” visit:

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0479, up 11.40%, on 19,054,731 volume with 967 trades. The average volume for the last 60 days is 6,256,653 and the stock's 52-week low/high is $0.019/$0.0728.

Recent News


Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that it has entered into private placement agreements with Harel Insurance, a leading Israeli institutional investor. Following the closing of the private placement, Harel Insurance will hold an aggregate of approximately 8.15% of Foresight’s issued share capital.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $3.3333, up 5.87%, on 21,069 volume with 106 trades. The average volume for the last 60 days is 42,954 and the stock's 52-week low/high is $2.44/$10.50.

Recent News


Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF)

The QualityStocks Daily Newsletter would like to spotlight Global Hemp Group, Inc. (GBHPF).

Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) ("GHG" or the "Company") is pleased to provide an update on its New Brunswick Hemp Project with joint venture partner, Marijuana Company of America Inc. (OTC Pink: MCOA) (the "Partners").

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTCQB: GBHPF), headquartered in British Columbia, Canada, is a publicly traded company founded in 2014. Global Hemp Group is focused on acquiring and developing a strategic portfolio of like-minded companies that believe in the significant potential of the industrial hemp plant. Global Hemp Group’s focused on attracting joint venture partners across all sectors of the industrial hemp industries with the commitment to improve quality of life by researching, developing and distributing sustainable materials, products and services produced from hemp.

The company’s mission is to build a strategic portfolio of hemp-based companies that operate synergistically to consistently deliver a solid ROI to its shareholders. Global Hemp Group has established the concept of Hemp Agro-Industrial Zone (HAIZ) ( in order to build cooperative mechanisms across industrial sectors with a focus on different parts of the hemp plant. Under the HAIZ strategy, Global Hemp Group brings together capital, farmers and labor in an effort to build a “soil-to-shelf” portfolio of complimentary companies and joint venture partners in the global hemp industry.

Global Hemp Group has chosen to only work with suppliers of high quality, sustainable raw materials and finished products derived from the hemp plant. Among the leading industries utilizing industrial hemp’s exceptional properties is the automotive sector, building materials market, bio-composites, energy-related markets, super-foods, nutritional supplements, nutraceuticals and the cannabinoid markets. Guided by the principal theme of “global environmental stewardship,” Global Hemp Group focuses on the key concepts of sustainability and social responsibility in all its endeavors.

Global Hemp Group’s joint venture with publicly traded Marijuana Company of America on hemp cultivation trials in 2017, designed to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada, for the first time in 20 years, was a great success. The partners are preparing for the upcoming changes in Canada’s cannabis legislation that will permit cannabinoid extraction from industrial hemp. Farmers have already been recruited to plant a minimum of 125 acres of industrial hemp for the 2018 growing season, with the goal of increasing the acreage under cultivation to 1,000+ acres by year three of the joint project. Global Hemp Group is preparing an application for a processing license to extract cannabidiol (CBD) and other cannabinoids from the upcoming industrial hemp crop. Discussions are also underway with potential processing partners for the extraction of cannabinoids and straw processing for building materials for the upcoming harvest in October 2018, with a longer term plan to establish permanent processing facilities by October 2019.

Global Hemp Group is led by Charles Larsen as its president, CEO and chairman of the board. Larsen’s more than 30 years of experience working in government, public, private and startup companies as an executive manager includes being the founding president of Medical Marijuana, Inc., the first public company in the Cannabis space. Larsen is also a founder and current director of Marijuana Company of America, Inc., and has been actively involved in the cannabis and hemp industry for nearly a decade. Larsen is joined by Curt Huber, who serves as CFO and director. Huber is an independent corporate and financial consultant with more than 25 years of experience in all facets of public companies among many different sectors including mining, oil and gas, and technology.

Also joining the management team as director is Dr. Paul T. Perrault, an agricultural economist trained in cooperative development and in rural development. Perrault’s experience includes years of consulting on rural development projects introducing new crops in several developing countries and strengthening agricultural research organizations, principally in Africa. Jeff Kilpatrick also serves as a director and is currently a program supervisor of Alachua County Department of Court Services in Gainesville, Florida. Kilpatrick, who spent 21 years in the U.S. Coast Guard, is a member of LEAP – Law Enforcement Against Prohibition – and is president elect for the National Association of Pretrial Services Agencies (NAPSA).

Global Hemp Group’s business philosophy is “A healthier future through sustainable business strategies.“

Global Hemp Group, Inc. (GBHPF), closed the day's trading session at $0.1393, up 6.34%, on 203,160 volume with 83 trades. The average volume for the last 60 days is 186,938 and the stock's 52-week low/high is $0.0115/$0.316.

Recent News


Pivot Pharmaceuticals Inc. (OTCQB: PVOTF)

The QualityStocks Daily Newsletter would like to spotlight Pivot Pharmaceuticals Inc. (PVOTF).

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) has a suite of CBD-based pet products in development, targeting indications such as inflammation, post-surgical pain and joint pain, as well as skin disorders. To view the full article, visit:

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

Pivot Pharmaceuticals Inc. (PVOTF), closed the day's trading session at $0.371, up 5.13%, on 146,139 volume with 33 trades. The average volume for the last 60 days is 138,339 and the stock's 52-week low/high is $0.047/$2.46.

Recent News


Medical Cannabis Payment Solutions (OTC: REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Cannabis-focused financial services company Medical Cannabis Payment Solutions (OTC: REFG) is currently focusing its efforts on expanding within the cannabis industry. To view the full article, visit:

Medical Cannabis Payment Solutions (OTC: REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.04, off by 2.44%, on 180,637 volume with 36 trades. The average volume for the last 60 days is 603,229 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News



The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

EVIO Inc. (OTCQB: EVIO) ("EVIO" or the "Company"), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, is pleased to announce that Donald R. Gibbs, CPA, CMA has joined EVIO's board of directors as independent director and chair of the audit committee.

EVIO, Inc. (OTCQB: EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed the day's trading session at $1.13, up 1.80%, on 130,720 volume with 81 trades. The average volume for the last 60 days is 85,719 and the stock's 52-week low/high is $0.47/$2.70.

Recent News


Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element, Inc. (NASDAQ: NETE) highlighted today in an article on small fintech companies making big waves in blockchain technology.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.506, off by 5.47%, on 204,825 volume with 875 trades. The average volume for the last 60 days is 441,315 and the stock's 52-week low/high is $2.556/$33.51.

Recent News


Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

The supply-demand imbalance in lithium is exemplified by reports that Li-ion battery consumption grew 73 percent from 2010 to 2014, whereas lithium production only increased 28 percent. Prospective junior miner Lithium Chile (TSX.V: LITH) (OTC: LTMCF) (LTMCF Profile) aims to capitalize on such deficits.

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.7314, off by 3.15%, on 62,752 volume with 64 trades. The average volume for the last 60 days is 22,591 and the stock's 52-week low/high is $0.5946/$0.9614.

Recent News


QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

A recently signed NDA contract through which spodumene mineralization at QMC’s Irgon Project located in Manitoba’s bountiful Cat Lake-Winnipeg River Pegmatite Field serves as evidence that QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) continues to advance toward the eventual reboot of a lithium mine that was shuttered some six decades ago.

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.3084, off by 5.98%, on 127,165 volume with 60 trades. The average volume for the last 60 days is 119,508 and the stock's 52-week low/high is $0.0748/$1.46.

Recent News

chart (OTCQB: CIIX)

The QualityStocks Daily Newsletter would like to spotlight (CIIX).

Recently, Warren Wang, CEO of (OTCQB: CIIX), talked about the company’s pending launch of its Bitcoin Trading Academy when he spoke with Donald Baillargeon of MoneyTV. Per the interview, the Academy will launch in July, and the company will promote its bilingual (English and Chinese) website ( in Asia (Singapore, Hong Kong, Taipei, and throughout Malaysia).

Founded in 1999, (OTCQB: CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website,, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site,, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. (CIIX), closed the day's trading session at $0.456, off by 3.75%, on 36,227 volume with 14 trades. The average volume for the last 60 days is 51,825 and the stock's 52-week low/high is $0.40/$1.58.

Recent News


BLOCKStrain Technology Corp. (TSX-V: DNAX)

The QualityStocks Daily Newsletter would like to spotlight BLOCKStrain Technology Corp. (DNAX).

Robert Galarza, Chief Executive Officer and Director, BLOCKStrain Technology Corp. (DNAX), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market today. Also today, NetworkNewsWire released a report on the company examining the appointment of Derek Pedro, an veteran of the legalized cannabis industry in Canada, to its advisory board.

BLOCKStrain Technology Corp. (TSX-V: DNAX), a full-service software company headquartered in Vancouver, BC, Canada, has developed the first integrated blockchain platform that registers and tracks cannabis intellectual property (“IP”) from genome to sale. It is proprietary, immutable and cryptographically secure, thereby establishing a single source of truth for cannabis strains and their ownership.

With Canada set to legalize marijuana use for recreational purposes, and other jurisdictions following suit around the world, new challenges will emerge regarding the ability to provide a safe and legal inventory of a product that up until now was largely only available on the black market. Cannabis will be heavily tested and regulated by numerous regulatory bodies in Canada. The cannabis industry faces unique challenges that BLOCKStrain specifically helps it address, including:

  • Mandatory Testing: Through BLOCKStrain’s platform and lab-testing partners, the process is more efficient and streamlined, cutting the administrative burden in half and getting products to market faster;
  • DNA Based Product Validation: The underlying blockchain technology creates a genetic fingerprint that identifies and validates the product electronically so any participant on the platform, including consumers, can view and track what’s happening with that product from genome to sale;
  • Intellectual Property: Third, and perhaps most importantly, the BLOCKStrain platform protects the intellectual property of growers and breeders. This is important for the industry’s growth as products evolve and develop. If a craft grower, for example, creates a popular strain with unique characteristics, it will be able to protect its intellectual property by simply registering the strain’s genome with BLOCKStrain and locking that data into the blockchain. It will reside there forever and will be readily accessible in the event of future disputes, bringing a level of trust to the industry and ensuring licensing fees are paid to all players in the market.


BLOCKStrain’s genetics verification process is authentic and incredibly effective. User groups register by creating an account with BLOCKStrain, which starts the process. Organizations and independent growers submit seeds, flower and post-extraction product for testing to a registered and approved testing facility, which then submits test results to BLOCKStrain. Pre-existing data of genetic cannabis strains can also be submitted via BLOCKStrain verification administrators, with those results being added to the user group’s blockchain account. Submissions are entered into BLOCKStrain, and the transaction is completed and recorded.

Each time an item is tested and verified by the network, a Registration Affidavit is auto-generated and given a unique “BLOCKStrain Address” along with a traceable QR Code. Producers, patients and consumers are able to not only verify the test but can also rate the product, write reviews and share opinions. This detail is stored within BLOCKStrain and, just like the test results, cannot be tampered with or modified. Verification and certification are earned by all parties for their participation.


BLOCKStrain demystifies the seed-to-sale process for all relevant stakeholders including producers, distributors, shippers, government agencies and consumers by creating a repository of cannabis genomes on an immutable, shared ledger. Thousands of cannabis strains exist and cultivators are breeding new strains all the time. The proliferation of cannabis strains can prove problematic for consumers since there are more than 500 known chemical compounds in a single plant. Furthermore, since several dozens of these compounds have been identified as pharmacologically active, it becomes more and more difficult for consumers to know what they are purchasing.

It is for this reason that being able to quantify the genetics, potency and equivalencies among cannabis products is crucial to the future of legalized cannabis. The difference is not so much in the name or brand attached to the cannabis, but the DNA of the plant itself. BLOCKStrain ensures product integrity, safety, regulatory compliance, product licensing and authenticity – all vital elements for the emerging cannabis industry.  This technology also bolsters the process of meeting government regulatory standards by providing real-time visibility of industry operations to agencies assigned to enforce and regulate cannabis activity.


BLOCKStrain allows for the defense of intellectual property rights for the grower with an authentic, verifiable chain of evidence embedded in the blockchain itself. Proof of ownership for a specific strain of cannabis is paramount in a multibillion dollar industry. Real life ownership disputes have already begun in the industry with legal battles underway. Unfortunately, the framework for resolving these disputes has yet to be defined and they are not likely to be resolved anytime soon.

Consumers and regulators alike want to know whether a cannabis product grown and sold at a local dispensary is safe and meets quality control standards. BLOCKStrain enhances trust of origin from genome-to-sale as cannabis flows through the supply chain, verifying critical steps in the process such as who is growing the plant, which seed is planted and where did it come from, whether pesticides were used, how much was grown, which tests are used to establish quality and potency, where the product is transported and how, and whether possession limits are meeting regulatory standards.

In summary, BLOCKStrain has developed the most comprehensive, secure and community-driven cannabis genetics archival platform for cannabis breeders and growers, large and small, to protect and release their varieties into the public domain, all while compensating and rewarding them for their contributions.

BLOCKStrain Technology Corp. (DNAX), closed the day's trading session at $0.34, off by 9.33%, on 495,430 volume. The stock's 52-week low/high is $0.1049/$1.20.

Recent News


Sharing Services, Inc. (OTC: SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services, Inc. (OTC: SHRV), a diversified holding company specializing in the direct selling industry, recently announced that it has appointed Stephen Gould Corp. as the new fulfillment and distribution partner to support its wholly owned subsidiary, Elevacity Global.

Sharing Services, Inc. (OTC: SHRV) headquartered in Plano, Texas, is a diversified holding company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth, and sending as many successful company “families” as possible on vacation.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders –  Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.33, off by 8.33%, on 42,999 volume with 9 trades. The average volume for the last 60 days is 34,794 and the stock's 52-week low/high is $0.125/$1.07.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.